← Markets

Corcept Therapeutics Incorporated

CORT · NASDAQ

Market closed$90.52$0.800000 (+0.89%)After hours $90.95 · +0.48%

Key statistics

Previous close$89.72
Open$87.97
Day high$91.45
Day low$87.22
52-week high$95.11
52-week low$28.66
Market cap9.72B
Volume1.86M
Average volume1.11M
P/E ratio258.63
Forward P/E—
EPS0.35
Dividend yield0.00%

Market context

Why it moved

Corcept Therapeutics (CORT) edged higher as positive sentiment surrounding the company's strong growth profile and its FDA resubmission of relacorilant for Cushing's syndrome outweighed concerns from insider share sales by a director and the CFO, which were executed under pre-arranged 10b5-1 trading plans.

TradingkeyQuiverquantYelpFacebookWedu

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Corcept Therapeutics edged higher, outperforming a softer healthcare sector (XLV) as investors continue to digest the company's landmark FDA approval of Relacorilant (Lifyorli) for advanced ovarian cancer in March 2026. The stock is benefiting from broader pharmaceutical tailwinds, with UBS upgrading the healthcare sector as a key allocation focus alongside AI, citing improving earnings revisions and a stabilizing regulatory environment. Corcept also draws attention from growth-focused investors due to its ~11% insider ownership and analyst forecasts of nearly 48% revenue growth, positioning it as a standout name in the pharma space amid an active earnings season.

0.8917

July 17, 2026Corcept Therapeutics closed essentially flat on the session but is surging over 3.6% in after-hours trading, building on momentum from the March FDA approval of Lifyorli (relacorilant) for platinum-resistant ovarian cancer. Investor focus remains on the upcoming relacorilant NDA resubmission for Cushing's syndrome, where analysts have lifted price targets to $88, while the company's raised 2026 revenue guidance of $950–$1,050M and 48.9% projected earnings growth have kept Corcept among highlighted high-insider-ownership growth names. A favorable healthcare macro backdrop — including UnitedHealth's strong Q2 beat and UBS upgrading the healthcare sector — may be adding to the after-hours lift.

0.1675

July 16, 2026Corcept Therapeutics closed modestly lower, edging down roughly 1%, as mixed healthcare sector sentiment weighed on the stock. The company continues to be highlighted as a top growth name with high insider ownership (~10.9%) and projected earnings growth of ~49%, following its landmark March FDA approval of Relacorilant (Lifyorli) for advanced ovarian cancer. State Street's upgrade of the healthcare sector outlook to positive for Q3 2026 offered a supportive tailwind, though broader pharmaceutical headwinds tied to Q2 earnings season uncertainty kept gains in check.

-0.9948

July 15, 2026Corcept Therapeutics surged over 5% — closing at $90.47 and extending gains to ~$92 in after-hours — as investor enthusiasm around Lifyorli (relacorilant) continues to build following its early FDA approval for platinum-resistant ovarian cancer. The rally comes amid a broader sector tailwind, with State Street upgrading its healthcare outlook to positive for Q3 2026 and a softer-than-expected June CPI report lifting risk sentiment across equities. Notably, an insider share sale by the chief development officer last week signals some profit-taking near record highs, though analyst consensus remains constructive with price targets lifted above $88 on the dual catalysts of Lifyorli's commercial ramp and the pending relacorilant NDA resubmission for Cushing's syndrome.

5.3201

July 14, 2026Corcept Therapeutics shares tumbled roughly 6.5% on broad market pressure stemming from renewed U.S.-Iran military tensions that sent oil prices surging and equity markets broadly lower. The selloff in CORT came despite an encouraging backdrop for the company: a recent Seeking Alpha Buy-rated analysis highlighted robust revenue growth and pipeline progress, while a May NDA resubmission for Relacorilant in Cushing's syndrome — after December's FDA rejection — has been a key catalyst watch. The stock is recovering modestly in after-hours trade, up ~0.7%, as investors assess the upcoming FDA decision on Relacorilant for platinum-resistant ovarian cancer.

-6.5085

July 11, 2026Corcept Therapeutics closed modestly lower, though after-hours activity surged nearly 3% as investors weighed a Seeking Alpha analysis reaffirming a Buy rating despite the recent relacorilant rejection for Cushing's syndrome. The stock remains near its 52-week high, underpinned by the March FDA approval of Lifyorli (relacorilant) for platinum-resistant ovarian cancer, raised 2026 revenue guidance of $950–$1,050 million, and positive Phase 2 data for dazucorilant in ALS. The broader biotech sector has been a quiet market leader, with XLV pushing record highs and Jim Cramer calling biotech 'the hottest group in the market right now.'

-1.4692

July 10, 2026Corcept Therapeutics closed modestly higher, hovering near its 52-week high as the stock continues to benefit from a powerful 2026 recovery narrative. The company has been buoyed by the early FDA approval of Lifyorli (relacorilant) for platinum-resistant ovarian cancer in March, a subsequent NDA resubmission for Cushing's syndrome in May, and raised 2026 revenue guidance of $950M–$1.05B. Healthcare has been the standout sector for two consecutive weeks, with XLV posting back-to-back gains, providing a constructive tailwind, while CNBC's Jim Cramer has called biotech 'the hottest group in the market' amid expectations of a wave of M&A activity under a friendlier FDA regime.

0.3335

July 9, 2026Corcept Therapeutics edged lower amid a broader market risk-off session triggered by the collapse of the U.S.-Iran ceasefire, which sent oil prices surging and stoked inflation fears. Despite the pullback, CORT remains near its 52-week high, buoyed by the March FDA approval of Relacorilant (Lifyorli) for ovarian cancer and a favorable sector tailwind — healthcare has been the market's top-performing sector, with XLV gaining 6.6% in June. Jim Cramer recently called biotech "the hottest group in the market," citing accelerating M&A activity under new FDA leadership, while analysts note capital rotation from crowded semiconductor trades into biotech.

-1.1697

Simply Wall Street · July 18, 2026Corcept Therapeutics (CORT) Stock Could Trade At A Discount As Its 346% Run LoomsStocktwits · February 25, 2026CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next CatalystSTAT · February 5, 2026Dispute between Corcept Therapeutics, FDA runs deepInvesting News Network · January 6, 2026Corcept Therapeutics Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman
Mt Newswire · June 17, 2026Corcept Therapeutics Resubmits NDA for Cushing's Syndrome Treatment Relacorilant
Benzinga · June 17, 2026Corcept Therapeutics Refiles Its New Drug Application With Additional Analyses Of Data To FDA For Relacorilant To Treat Cushing's Syndrome
Benzinga · June 8, 2026Reported Saturday, CATALYST Trial Data Show Korlym Reduces HbA1c By 1.3% And Body Weight By 5.1 Kg In Hypercortisolism Patients With Difficult-To-Control Diabetes
Mt Newswire · June 4, 2026Corcept Therapeutics Insider Sold Shares Worth $1,412,000, According to a Recent SEC Filing
Benzinga · June 3, 2026Corcept Therapeutics Discloses Amended Complaint Filed By Former Employee, Will Defend Itself Against Claims
Mt Newswire · June 1, 2026Corcept Therapeutics Insider Sold Shares Worth $325,000, According to a Recent SEC Filing
Mt Newswire · June 1, 2026Corcept Therapeutics Insider Sold Shares Worth $4,918,944, According to a Recent SEC Filing
Benzinga · May 29, 2026Corcept Therapeutics Announces New Overall Survival Data From Its Pivotal Phase 3 ROSELLA Trial Of Lifyorli Plus Nab-Paclitaxel In An Oral Presentation At The ASCO 2026; Patients Treated With Lifyorli Combined With Nab-Paclitaxel Experienced A 35 Percent Reduction In The Risk Of Death Compared To Patients Treated With Nab-paclitaxel Alone

Peers

S&P 500SPX · $7,457.69-1.01%Vertex Pharmaceuticals IncorporatedVRTX · $485.65-0.08%Alnylam Pharmaceuticals, Inc.ALNY · $267.47-5.54%Regeneron Pharmaceuticals, Inc.REGN · $676.69-0.33%Supernus Pharmaceuticals, Inc.SUPN · $48.04-0.35%Jazz Pharmaceuticals plcJAZZ · $247.53+2.21%Royalty Pharma plcRPRX · $58.18-0.60%Zoetis Inc.ZTS · $76.56-0.46%Vanda Pharmaceuticals Inc.VNDA · $5.44-0.18%BioMarin Pharmaceutical Inc.BMRN · $59.59-0.68%Annovis Bio, Inc.ANVS · $1.740.00%SK Biopharmaceuticals Co., Ltd.326030.KS · 79,400.00+1.53%